SCHEMBL24899569

SCHEMBL24899569

c1ccc(-c2ccc(N(c3ccc4ccccc4c3)c3cc(-c4nc(-c5ccccc5)nc(-c5ccccc5)n4)c4c(c3)oc3ccccc34)cc2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.34
ALDH1A1 P00352 5/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
CYP1A2 P05177 3/20 0.34
KMT2A Q03164 3/20 0.34
HSD17B10 Q99714 2/20 0.34
MEN1 O00255 2/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 6/20 0.33
NR1H4 Q96RI1 1/20 0.33
POLB P06746 2/20 0.31
TERT O14746 2/20 0.31
TSHR P16473 3/20 0.31
HPGD P15428 2/20 0.31
KDM1A O60341 1/20 0.31
ALOX15 P16050 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
LMNA P02545 3/20 0.30
GLA P06280 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25666438 0.97 MAPT (0.33) KDM4EALDH1A1SMN1; SMN2CYP1A2KMT2A
SCHEMBL24899587 0.97 ALDH1A1 (0.33) KDM4EALDH1A1SMN1; SMN2CYP1A2KMT2A
SCHEMBL24066124 0.96 KDM4E (0.36) KDM4EALDH1A1SMN1; SMN2CYP1A2KMT2A
SCHEMBL25975707 0.94 ALDH1A1 (0.33) KDM4EALDH1A1SMN1; SMN2CYP1A2KMT2A
SCHEMBL24255422 0.94 KDM4E (0.36) KDM4EALDH1A1SMN1; SMN2CYP1A2KMT2A
SCHEMBL22112409 0.93 ALDH1A1 (0.34) KDM4EALDH1A1SMN1; SMN2CYP1A2KMT2A
SCHEMBL24255398 0.93 KDM4E (0.33) KDM4EALDH1A1SMN1; SMN2CYP1A2KMT2A
SCHEMBL25975709 0.93 KDM4E (0.36) KDM4EALDH1A1SMN1; SMN2CYP1A2KMT2A
SCHEMBL24255395 0.92 ALDH1A1 (0.34) KDM4EALDH1A1SMN1; SMN2CYP1A2KMT2A
SCHEMBL24255426 0.92 ALDH1A1 (0.34) KDM4EALDH1A1SMN1; SMN2CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230128360-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DEVICE LT MATERIALS CO., LTD. (KR) 2023-04-27 US disclosed
US-20230128360-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DEVICE LT MATERIALS CO., LTD. (KR) 2023-04-27 US disclosed
EP-4137488-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DEVICE LT Materials Co., Ltd. (KR) 2023-02-22 EP disclosed
US-20230016632-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, COMPOSITION FOR ORGANIC MATERIAL LAYER OF ORGANIC LIGHT-EMITTING DEVICE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT-EMITTING DEVICE LT MATERIALS CO.,LTD. (KR) 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128360-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DEVICE CRY1, ORC3, ODC1 KDM4E 3080/4885ALDH1A1 27/4885SMN1; SMN2 4152/4885
US-20230016632-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, COMPOSITION FOR ORGANIC MATERIAL LAYER OF ORGANIC LIGHT-EMITTING DEVICE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT-EMITTING DEVICE CYP1A1, CYP1B1, CRY1 KDM4E 3329/4885ALDH1A1 23/4885SMN1; SMN2 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.